C-Reactive Protein

C-reactive protein (CRP) is a circulating protein produced predominantly by the liver whose concentration increases during the acute-phase response to inflammation, infection, and tissue injury. It belongs to the pentraxin family and normally circulates as a ring-shaped assembly of five identical subunits. CRP participates in innate immunity by recognizing molecular features of microorganisms and damaged host cells and interacting with the complement system. (ncbi.nlm.nih.gov)

CRP is widely used as a biomarker for detecting and monitoring inflammatory responses. An elevated concentration does not identify a particular disease or establish where inflammation occurs, so its clinical meaning depends on other findings. Standard CRP assays principally assess inflammatory conditions, whereas high-sensitivity CRP (hs-CRP) assays measure lower concentrations of the same protein and are used in cardiovascular risk assessment. Understanding CRP therefore requires distinguishing its molecular and immune functions from the information provided by its measurement in blood. (medlineplus.gov)

Discovery, Naming, and Research Milestones

In 1930, William S. Tillett and Thomas Francis Jr., working at the Hospital of the Rockefeller Institute for Medical Research, reported that serum from patients with acute lobar pneumonia formed a precipitate when mixed with a nonprotein somatic fraction of pneumococcus, designated “Fraction C.” Their paper, published on September 30 in the Journal of Experimental Medicine, compared serum reactions during illness and convalescence. The C-fraction reaction was strong during acute illness but was no longer demonstrable after the crisis—the abrupt clinical turning point toward recovery. The investigators also observed positive reactions in some patients with streptococcal or staphylococcal infections and acute rheumatic fever, showing that the phenomenon was not restricted to pneumococcal pneumonia. (pmc.ncbi.nlm.nih.gov)

The name “C-reactive” refers to this reaction with pneumococcal C substance, subsequently described as C polysaccharide; the letter does not designate a vitamin or blood group. The nonprotein bacterial fraction must be distinguished from the serum protein that reacted with it. In 1941, Theodore J. Abernethy and Oswald T. Avery reported evidence for the protein nature of the serum component: heating above $65\,^\circ\mathrm{C}$ abolished its precipitation activity, and the reactive material occurred in the serum albumin fraction. They also established that calcium ions were required for flocculation with C polysaccharide. These experiments helped distinguish the acute-phase serum reaction from a conventional pathogen-specific antibody response. (centennial.rucares.org)

A major sequence milestone followed in 1985, when K. J. Lei and colleagues published “Genomic DNA sequence for human C-reactive protein” in the Journal of Biological Chemistry. They isolated the human gene from two genomic DNA libraries using synthetic oligonucleotide probes. Its sequence predicted a mature chain of 206 amino acids, correcting the previously reported length of 187 by identifying an additional 19 residues beginning at position 62. The study separately identified an 18-residue signal peptide, preventing confusion between the secreted mature chain and its precursor. This provided a corrected sequence framework for subsequent structural investigations. (pubmed.ncbi.nlm.nih.gov)

In April 1996, A. K. Shrive and colleagues published a three-dimensional structure of human CRP in Nature Structural Biology. Determined by X-ray crystallography, the structure supplied an atomic framework for investigating molecular recognition. It indicated that binding of phosphocholine involved calcium and a hydrophobic pocket centered on phenylalanine 66, with glutamate 81 positioned to interact with the choline group. The authors also identified a cleft on the opposite face of the pentamer as a possible functional site; this was a structural hypothesis rather than a direct demonstration of its biological activity. (pubmed.ncbi.nlm.nih.gov)

In 1999, D. Thompson, M. B. Pepys, and S. P. Wood reported structures of calcium-loaded CRP both with and without bound phosphocholine in Structure. Direct visualization of the ligand showed its phosphate group interacting with two protein-bound calcium ions and its choline group contacting glutamate 81. These structures refined the earlier interpretation by locating phosphocholine in a shallow pocket on each subunit. They also provided a geometric explanation for attachment to phosphocholine-bearing surfaces while leaving the opposite face accessible to components of the complement system, connecting the original precipitation phenomenon to a defined molecular recognition mechanism. (sciencedirect.com)

Molecular Structure and Pentraxin Classification

C-reactive protein (CRP) belongs to the pentraxin family of soluble recognition proteins and, together with serum amyloid P component (SAP), forms the classical short-pentraxin group. CRP and SAP share a closely related subunit fold and pentameric organization, but they are distinct proteins with different ligand preferences: CRP preferentially recognizes phosphocholine, whereas SAP binds phosphoethanolamine. The designation “short” distinguishes their compact pentraxin-domain architecture from that of pentraxin 3 (PTX3), a long pentraxin with an additional N-terminal region. Family membership does not require every pentraxin to form a five-membered ring: a 2022 structural study resolved the C-terminal domains of PTX3 as a disulfide-stabilized octamer, markedly different from the CRP pentamer. (pubmed.ncbi.nlm.nih.gov)

Native human CRP comprises five identical subunits, each containing 206 amino acid residues and having a molecular mass of approximately 23 kDa; the assembled pentamer therefore has a mass of approximately 115 kDa. The subunits associate noncovalently and have the same orientation around a central opening, producing a flattened ring with fivefold rotational symmetry. Each subunit is built around a jellyroll fold, in which two layers of β-sheet form the structural core. In their 1999 X-ray crystallographic analysis, D. Thompson, M. B. Pepys, and S. P. Wood found that this fold closely resembles that of SAP, although CRP subunits are tipped toward the fivefold axis. The resulting assembly has two structurally distinct faces rather than five independently oriented recognition units. (pmc.ncbi.nlm.nih.gov)

Each subunit carries one phosphocholine-binding pocket on the same face of the ring, giving the pentamer five recognition sites. Two calcium ions occupy each site and directly coordinate the phosphate group of the bound ligand. Calcium thus participates in the binding interface rather than merely accompanying the protein in solution. The choline portion fits into a shallow pocket whose specificity depends on several side chains: Phe66 makes hydrophobic contacts with its three methyl groups, Glu81 interacts with its positively charged nitrogen, and Thr76 helps establish the pocket’s dimensions. In SAP, the position corresponding to CRP’s Thr76 contains Tyr74, illustrating how closely related folds can support different ligand preferences. These residue-level interactions account for the combination of calcium dependence and chemical selectivity in CRP’s molecular recognition. (pubmed.ncbi.nlm.nih.gov)

The phosphocholine-binding surface is conventionally termed the recognition face, whereas the opposite surface is termed the effector face because it participates in interactions with the complement system. This opposite face contains a cleft bordered by an α-helix; mutational experiments have implicated Asp112 and Tyr175 in recognition by C1q, the recognition component of the classical complement pathway. The spatial separation allows ligand-binding sites to engage a target while leaving the opposite surface available for complement interactions. It does not mean that an unbound pentamer continuously activates complement: target binding and the presentation of CRP molecules are important parts of the interaction. The molecular geometry therefore separates recognition of phosphocholine-containing structures from recruitment of an immune effector, without assigning both functions to the same binding pocket. (pubmed.ncbi.nlm.nih.gov)

The CRP Gene and Regulation of Production

The human CRP gene lies at 1q23.2, on the long arm of chromosome 1. The italicized symbol CRP denotes the DNA locus, whereas CRP in ordinary type denotes its encoded protein, C-reactive protein. These represent different levels of biological organization: the gene supplies the coding and regulatory information, while circulating CRP is the secreted product measured in blood. NCBI’s reference annotation identifies CRP as a protein-coding gene and reports strongly liver-predominant expression, consistent with the liver’s role as the principal source of circulating CRP. (ncbi.nlm.nih.gov)

The original genomic sequencing study, published in 1985 by K. J. Lei and colleagues, distinguished the precursor from the mature secreted chain. It identified coding sequences for an 18-amino-acid signal peptide followed by a mature protein of 206 amino acids, giving a precursor length of 224 residues. The signal peptide provides the targeting sequence for secretion and is removed during maturation; it is not part of the mature circulating subunit. The sequenced gene contained a 278-base-pair intron after the sequences encoding the signal peptide and the first two residues of mature CRP, with the remaining 204 residues encoded downstream. The DNA sequence also corrected an earlier estimate of 187 residues for the mature chain by revealing 19 additional amino acids beginning at position 62. Thus, 224 and 206 describe precursor and mature-chain lengths, respectively, rather than competing measurements of the same molecular form. (pubmed.ncbi.nlm.nih.gov)

CRP production increases through cytokine-dependent regulation of gene expression in hepatocytes, the principal functional cells of the liver. Interleukin-6 (IL-6) is a major inducing cytokine. In a 1988 study, José V. Castell and colleagues found that recombinant human IL-6 produced a 23-fold increase in CRP synthesis in cultured human hepatocytes under the experimental conditions. Their subsequent studies showed induction at both messenger-RNA and protein levels. In experiments comparing IL-6, interleukin-1β (IL-1β), and tumor necrosis factor-α, only IL-6 independently induced CRP in the tested primary hepatocyte cultures. These findings establish a production mechanism: inflammatory signals stimulate hepatic synthesis and secretion, rather than CRP simply being discharged from injured tissue. The experimental fold increase describes that culture system, not a fixed response in every human inflammatory episode. (pubmed.ncbi.nlm.nih.gov)

At the transcriptional level, IL-6 activates regulatory proteins including STAT3 and members of the C/EBP family. Their interaction with CRP regulatory DNA connects extracellular cytokine signals to increased transcription. IL-1β can amplify this response: in the human hepatoma cell line Hep3B, it does not independently induce CRP but synergistically enhances IL-6-induced expression, with NF-κB participating in the regulatory response. A 2022 study by Donald N. Ngwa, Asmita Pathak, and Alok Agrawal identified STAT3 binding at four sites in the proximal CRP promoter. Mutation of three individually tested sites reduced cytokine-induced expression. These cell-based experiments demonstrate that induction depends on coordinated regulatory interactions, not merely the presence of one cytokine or one promoter sequence. (pmc.ncbi.nlm.nih.gov)

Inherited sequence variation also contributes to differences in circulating CRP concentration. In a 2008 study by Jeppe Zacho and colleagues, the AA genotype at rs1205 was associated with CRP concentrations 23% lower than those associated with GG, while AA at the promoter variant rs3091244 was associated with concentrations 67% higher than CC. Combinations of the four examined variants differed in concentration by up to 64%. These are genotype-associated population differences, not deterministic predictions for an individual blood measurement. Importantly, the CRP-raising genotype combinations were not associated with increased ischemic vascular disease risk in that study. A genetic influence on protein concentration therefore does not itself establish causation of disease by that protein. (nejm.org)

Acute-Phase Response and Circulating Kinetics

CRP is a positive acute-phase reactant: its circulating concentration increases because inflammatory signals stimulate production, predominantly in the liver. Cytokines released during inflammation connect events in affected tissues to this systemic response. Consequently, a rise in blood CRP is not simply leakage of pre-existing protein from injured cells. Tissue injury and infection can initiate the signals that increase synthesis, but the measured concentration represents the liver’s response to those signals rather than direct release from the damaged site. (medlineplus.gov)

After the onset of an acute-phase response, serum CRP typically begins rising within approximately 6–12 hours and reaches a peak around 24–48 hours. These intervals describe a usual response pattern, not a fixed timetable for every inflammatory event. The strength and duration of the stimulus affect both the magnitude of the increase and whether a distinct peak occurs. Severe stimuli, including major trauma and sepsis, can produce concentrations above 100 mg/L. An early measurement may therefore precede much of the increase, while continued inflammatory stimulation can sustain high concentrations beyond the usual peak interval. (mayocliniclabs.com)

The principal human turnover experiment was published in 1993 by David M. Vigushin, Mark B. Pepys, and Philip N. Hawkins. They administered human CRP labeled with iodine-125 to 8 healthy controls and 35 hospitalized patients, including people with rheumatoid arthritis, systemic lupus erythematosus, infections, and neoplasia. Plasma disappearance closely followed a monoexponential curve, with an approximately 19-hour half-life. Clearance was similar across the studied groups, and the fractional catabolic rate was independent of circulating CRP concentration; no accelerated breakdown was detected in the diseases examined. (jci.org)

These findings explain why reduced synthesis leads to falling concentrations without requiring an increase in clearance. As a simplified kinetic illustration, if additional production ceased entirely, the existing circulating pool would decline approximately according to

Thus, about one-half would remain after 19 hours and one-quarter after 38 hours. This is an illustration derived from the measured half-life, not a prediction that every patient’s result must follow that curve: continuing synthesis changes the observed decline. (jci.org)

Serial measurements therefore describe a changing inflammatory response rather than a fixed characteristic of a disease. A rising value can reflect ongoing stimulation, whereas a declining value can reflect diminishing production while previously synthesized CRP is cleared. The interval between samples and their timing relative to the inflammatory event matter. For example, after surgery, persistent or renewed increases differ kinetically from a resolving response, although CRP measurements alone do not establish the cause of that pattern. (mayocliniclabs.com)

Recognition of Microorganisms and Damaged Cells

CRP functions as a soluble recognition molecule of innate immunity, connecting the detection of microbial or altered host surfaces to mechanisms that remove them. It is not an antigen-specific antibody: its recognition depends on binding particular molecular structures, including phosphocholine, that may occur on both microorganisms and damaged cells. A well-characterized microbial target is the phosphocholine-bearing C-polysaccharide of the Streptococcus pneumoniae cell wall. Recognition of this chemical group allows CRP to bind pneumococci without requiring an antibody response directed against their particular capsular antigens. Target binding can then recruit soluble blood proteins and cellular effectors rather than directly destroying the target. (ncbi.nlm.nih.gov)

The canonical interaction with phosphocholine is calcium-dependent. The 1999 structural study by Darren Thompson, Mark B. Pepys, and Steve P. Wood identified a shallow ligand-binding pocket on each CRP subunit, providing a molecular explanation for recognition of phosphocholine-containing compounds. However, the presence of the chemical group alone does not determine whether a larger structure binds effectively: its accessibility and presentation on a membrane or polysaccharide surface also matter. In model-membrane experiments, CRP binding to phosphatidylcholine bilayers required incorporation of lysophosphatidylcholine, demonstrating the importance of altered lipid organization. In 2002, Mi-Kyung Chang and colleagues showed that CRP recognized phosphocholine on oxidized phosphatidylcholine and oxidized low-density lipoprotein, but not their native, nonoxidized counterparts under the experimental conditions. They also demonstrated recognition of related structures on cells undergoing apoptosis. (pubmed.ncbi.nlm.nih.gov)

Target-bound CRP can interact with C1q and initiate the classical pathway of the complement system. Complement deposition provides additional recognition signals for phagocytic cells, linking CRP binding to opsonization and subsequent uptake. The position of those signals can be decisive. In a 1984 study, T. J. Holzer and colleagues compared pneumococcal serotypes 27 and 4. CRP bound throughout the capsule and cell wall of serotype 27, promoting C3 deposition in the capsule and enhancing responses by human neutrophils and monocytes. In serotype 4, CRP binding was restricted to the cell-wall region and did not similarly enhance those responses. Thus, detectable binding and complement activation did not invariably produce effective opsonophagocytosis; the location of complement deposition relative to the bacterial capsule influenced the outcome. (pubmed.ncbi.nlm.nih.gov)

CRP also interacts experimentally with cellular receptors, including Fcγ receptors ordinarily associated with antibody-mediated responses. In a 2006 study of human peripheral-blood mononuclear cells, CRP-coated pneumococci increased production of the cytokines TNF-α and IL-1β. Blocking FcγRI or FcγRII, or inhibiting their signaling, reduced these responses. Such experiments demonstrate a route by which soluble recognition can influence blood-borne leukocytes, but receptor dependence varies with the endpoint and model. In a 2002 mouse infection study, administered human CRP retained protection in several Fcγ-receptor-deficient strains, whereas complement depletion or deficiency of C3 or C4 abolished protection. These findings distinguish receptor-mediated cellular signaling from complement-dependent protection in that experimental infection model. (pubmed.ncbi.nlm.nih.gov)

Recognition of damaged host cells can support removal without necessarily causing terminal complement-mediated lysis. In 2000, Debra Gershov and colleagues found that human CRP bound apoptotic lymphocytes in a calcium-dependent manner, increased early classical-pathway activation, and enhanced phagocytosis by macrophages. In their system, CRP also limited assembly of terminal complement components, and increased uptake was associated with macrophage expression of transforming growth factor β. These effects required C1q and factor H and were not maintained after the cells became necrotic. The results provide experimental evidence for coordinated recognition and clearance of dying cells; the authors’ proposed implications for systemic autoimmunity were not demonstrations that CRP prevents or causes a particular human autoimmune disease. (pmc.ncbi.nlm.nih.gov)

Pentameric and Monomeric Forms

Circulating CRP is predominantly pentameric CRP (pCRP): five identical protein subunits associated noncovalently in a ring. Monomeric CRP (mCRP) consists of dissociated subunits whose conformation and exposed surfaces differ from those in the intact pentamer. The distinction therefore involves both physical assembly and structural rearrangement, not a separate gene product. Whereas pCRP is soluble in plasma, mCRP has been identified on cell surfaces and in inflamed tissue. Its physical properties also depend on preparation: a 2020 study obtained soluble monomers of approximately 23 kDa using mild urea treatment, illustrating that experimentally produced monomeric preparations need not have identical properties. (pubmed.ncbi.nlm.nih.gov)

In 2009, Steffen U. Eisenhardt and colleagues demonstrated a cell-surface mechanism for converting pCRP into mCRP. Activated platelets, but not resting platelets, supported dissociation through lysophosphatidylcholine exposed on their surfaces. Conversion also occurred on hydrogen-peroxide-treated THP-1 monocytic cells and Jurkat T cells undergoing apoptosis. These experiments identified particular membrane conditions capable of promoting dissociation; they did not establish that every activated platelet or apoptotic cell necessarily converts CRP in vivo. In the same investigation, mCRP produced stronger monocyte responses than pCRP, including directed migration, activation-associated conformational change in the integrin Mac-1, reactive oxygen species generation, and adhesion under both static and physiological-flow conditions. (pubmed.ncbi.nlm.nih.gov)

Conformation-specific monoclonal antibodies distinguish structural states by recognizing epitopes exposed or concealed during rearrangement. For example, antibody 3H12 recognizes residues 199–206, largely located at the interface between subunits in native pCRP, whereas 8D8 recognizes a native conformational feature. Eisenhardt’s 2009 study reported mCRP deposition in human aortic and carotid atherosclerotic plaques, with neither mCRP in healthy vessels nor detectable pCRP in the examined healthy or diseased vessels. These findings require a methodological qualification: a 2017 study identified an altered but still pentameric intermediate, termed pCRP*, that exposes epitopes also recognized by antibodies used to detect mCRP. Using additional biochemical discrimination, that study found both mCRP and substantial pentameric CRP in carotid endarterectomy specimens. Antibody recognition of an exposed epitope alone therefore does not always demonstrate complete separation into monomers. (pmc.ncbi.nlm.nih.gov)

A study published online in 2011 extended the comparison to platelet activation and blood-flow experiments. Investigators measured aggregation and used flow cytometry to assess surface P-selectin, CD63 exposure, and activation of glycoprotein IIb–IIIa. Under the tested conditions, mCRP significantly increased these responses, whereas pCRP did not. Inhibitors of p38 MAP kinase and Jun N-terminal kinase, and an antibody blocking CD36, partially reduced mCRP-induced activation and aggregation. The investigators also observed dephosphorylation of vasodilator-stimulated phosphoprotein at serine 239. During perfusion of human blood containing pCRP over adhered activated platelets, confocal microscopy detected local generation of mCRP, which promoted further platelet recruitment. These were measured laboratory effects rather than evidence that circulating CRP invariably causes thrombosis in patients. (pubmed.ncbi.nlm.nih.gov)

Research measurements of these conformations are distinct from established clinical CRP blood tests. A 2019 assay-development study explicitly distinguished serum pCRP’s established use as an inflammatory biomarker from the unresolved diagnostic significance of mCRP. Tissue staining, structural discrimination, and cell-response experiments address localization and biological activity; they do not themselves establish clinical decision thresholds for tissue-associated mCRP or validate its use in routine diagnosis. (pubmed.ncbi.nlm.nih.gov)

Laboratory Measurement and High-Sensitivity Assays

Circulating CRP is measured in a blood sample, usually obtained by venipuncture. Serum is a commonly specified specimen, although some assay systems also accept validated plasma specimens; the acceptable specimen type depends on the method rather than on CRP measurement in general. For example, Mayo Clinic Laboratories’ high-sensitivity assay specifies serum collected in a serum-gel or red-top tube, followed by centrifugation and transfer into a plastic vial. Its requested submission volume is 1 mL, with a minimum of 0.2 mL. Roche’s Cardiac C-Reactive Protein (Latex) High Sensitive assay is intended for quantitative measurement in human serum and plasma on specified cobas systems. (medlineplus.gov)

Particle-enhanced immunoturbidimetry uses latex particles coated with monoclonal antibodies directed against CRP. CRP in the specimen binds the particle-associated antibodies, producing antigen-dependent agglutination. The resulting aggregates increase the reaction mixture’s turbidity, which the analyzer measures optically and converts into a concentration through calibration with materials of assigned CRP concentration. Both Mayo’s conventional CRP test and its high-sensitivity test use this general principle: “high sensitivity” therefore does not necessarily indicate a different detection technology. Reagent formulation, instrument settings, calibration, and validated performance determine the concentrations that a particular implementation can measure reliably. (mayocliniclabs.com)

Conventional and high-sensitivity assays measure the same protein; hs-CRP is not a separate molecular species. Conventional testing is generally used to assess or monitor inflammatory disorders, where concentrations may rise into tens or hundreds of milligrams per litre. High-sensitivity testing emphasizes precise measurement at low baseline concentrations and is used in cardiovascular risk assessment. As a concrete analytical example, Roche’s May 2024 method sheet for the cobas c 701/702 hs-CRP application specifies a measuring range of 0.15–20.0 mg/L, with automated dilution and repeat analysis for higher concentrations. This is an assay’s measurement range, not a reference interval or a boundary between health and disease. (medlineplus.gov)

Analytical sensitivity includes distinctions between detecting an analyte and measuring it reproducibly. The same Roche application specifies a lower detection limit of 0.15 mg/L, whereas its functional sensitivity is 0.3 mg/L, defined as the lowest concentration measurable with an inter-assay coefficient of variation below 10%. These figures illustrate why a detectable signal does not automatically imply equally precise quantification. Calibration, quality-control limits, and dilution procedures are method-specific requirements. Moreover, improved analytical sensitivity does not confer specificity for a particular disease: an accurately measured CRP elevation remains a nonspecific biomarker of inflammation, rather than an independent diagnosis of its cause or location. (elabdoc-prod.roche.com)

Specimen handling and interference criteria likewise belong to the individual laboratory procedure. Mayo’s hs-CRP service specifies serum stability of seven days refrigerated or 30 days frozen and rejects specimens with gross hemolysis, lipemia, or icterus. Its documentation also identifies possible falsely decreased results after treatment with carboxypenicillins and reports no significant rheumatoid-factor interference up to 200 IU/mL. Such acceptance criteria and interference limits should not be generalized to every CRP assay. Separately from these analytical issues, biological variation can make a single hs-CRP measurement unrepresentative of an individual’s baseline concentration, even when the specimen and measurement meet laboratory requirements. (mayocliniclabs.com)

Units, Reference Intervals, and Interpretive Limitations

Circulating CRP is reported as a mass concentration, usually in milligrams per liter (mg/L) or milligrams per deciliter (mg/dL). Because one liter contains ten deciliters, $1\,\mathrm{mg/dL}=10\,\mathrm{mg/L}$: a result of 0.5 mg/dL is therefore identical to 5 mg/L, not ten times lower. Numerical comparisons require matching units as well as the type of test. For example, MedlinePlus states that most healthy adults have CRP concentrations below 0.3 mg/dL, equivalent to 3 mg/L, whereas Mayo Clinic Laboratories lists a reference value below 5.0 mg/L for its conventional serum CRP assay. These figures serve different descriptive purposes and do not establish interchangeable diagnostic boundaries. (medlineplus.gov)

A reference interval describes results in a defined reference population, generally selected to represent healthy individuals; a clinical decision threshold is a concentration used for a particular diagnostic, prognostic, or risk-classification purpose. A laboratory flag indicating that CRP exceeds its reference limit is consequently not itself a diagnosis. Laboratories may use different methods and reference populations, and the applicable interval is the one associated with the reported assay. Results outside an interval can occur in healthy people, while results inside it can occur in people with disease. Conventional CRP interpretation and high-sensitivity CRP assessment of cardiovascular risk also address different questions: hs-CRP measures the same protein at low concentrations, but its risk categories are not universal definitions of “normal CRP.” (medlineplus.gov)

An elevated concentration is a nonspecific biomarker of inflammation: it neither identifies the initiating cause nor locates the affected tissue. Infection, inflammatory disorders, and tissue injury can produce overlapping results, so the concentration alone cannot distinguish these processes. Conversely, a low result does not exclude every inflammatory condition. MedlinePlus specifically notes that CRP may remain unraised in some people with rheumatoid arthritis or systemic lupus erythematosus. Interpretation therefore depends on the clinical findings, medical history, and other investigations rather than on a positive-versus-negative reading of the CRP value alone. (medlineplus.gov)

Physiological circumstances and exposures can shift concentrations independently of an acute infection. Obesity is associated with higher CRP, and elevations can occur during the latter half of pregnancy, with oral contraceptives, or during menopausal hormone therapy. Route of hormone administration can matter. In a 2003 randomized crossover study of 21 postmenopausal women, Wanpen Vongpatanasin and colleagues found that eight weeks of oral conjugated estrogen increased CRP more than twofold, whereas transdermal estradiol did not increase it. The investigators proposed first-pass hepatic effects as an explanation. Such observations establish factors relevant to interpretation, not a means of attributing an individual elevated result to obesity, pregnancy, or a medication without other evidence. (medlineplus.gov)

Liver dysfunction introduces a different limitation because the liver produces circulating CRP: the response to infection can be attenuated in cirrhosis. This does not mean that all patients with liver disease have low CRP. A 2012 study by Maria Papp and colleagues examined 368 patients with cirrhosis, including 139 with documented infection; CRP distinguished infection less accurately in advanced disease, partly because noninfected patients already had elevated concentrations. Thus, impaired responsiveness and an elevated baseline can both complicate interpretation in liver disease, weakening any simple correspondence between the measured concentration and the presence or severity of infection. (pubmed.ncbi.nlm.nih.gov)

Clinical Uses in Infection and Inflammatory Disease

CRP measurement serves as an adjunct to the assessment of infection, documenting the inflammatory response rather than detecting a pathogen. Its interpretation combines the blood result with symptoms, examination findings, imaging, and microbiological testing; both bacterial and viral infections can raise CRP. In hospitalized patients with pneumonia, serial measurements can help assess response to treatment. The United Kingdom’s 2025 NICE guideline describes measurement 3–4 days after treatment begins when there is clinical concern about treatment failure, noting that persistently high concentrations or a lack of substantial improvement are associated with failure. In suspected sepsis, CRP forms part of a broader laboratory assessment that includes blood cultures, lactate, blood counts, and measures of organ function. It does not independently establish sepsis or identify the infecting organism. (medlineplus.gov)

In rheumatoid arthritis, CRP is used to monitor inflammatory activity and changes during anti-inflammatory treatment, but it is not a direct measurement of joint damage. The CRP-based Disease Activity Score in 28 joints, DAS28-CRP, combines the laboratory concentration with tender and swollen joint counts and a patient-reported assessment of general health. This composite approach places the blood measurement alongside clinical evidence rather than treating it as a complete description of disease activity. Some patients with rheumatoid arthritis have inflammation without an elevated CRP, so a low concentration alone does not establish remission. (medlineplus.gov)

For inflammatory bowel disease, CRP provides a systemic biomarker that complements symptoms, stool markers, and assessment of intestinal inflammation. The American Gastroenterological Association’s November 2023 guideline for Crohn’s disease illustrates how its meaning depends on clinical context. In patients in symptomatic remission with recently confirmed endoscopic remission, unchanged clinical status, and stable treatment, CRP below 5 mg/L—or the laboratory’s normal-range cutoff—and/or fecal calprotectin below 150 µg/g can help rule out active inflammation and avoid routine endoscopic reassessment. Conversely, elevated biomarkers during symptomatic remission support endoscopic assessment rather than an automatic treatment change. Mild symptoms accompanied by normal biomarkers also warrant endoscopic assessment under this framework, demonstrating that symptoms and blood results may diverge. (gastro.org)

After surgery, tissue injury itself produces an inflammatory response, making an early CRP elevation distinct from evidence of postoperative infection. A 2008 study of 201 patients admitted for elective general surgery found that CRP generally peaked on postoperative day 2 or 3 and then fell; patients with elevated preoperative concentrations had higher, later peaks. Consequently, an isolated early postoperative result has limited value as an infection screen. Subsequent trajectories can contribute to assessment of recovery or complications, but the pattern is not specific to infection: a study of 153 patients after open-heart surgery found that secondary rises after the third postoperative day accompanied both infectious and noninfectious complications. Falling CRP during treatment or recovery is evidence of a diminishing inflammatory response, not identification of its original cause. (pubmed.ncbi.nlm.nih.gov)

CRP and erythrocyte sedimentation rate (ESR) are commonly used together, but measure different phenomena. CRP testing measures a circulating protein concentration; ESR measures how rapidly red blood cells settle in a tube, a process accelerated by inflammation-associated cell aggregation. Their results can therefore provide complementary information without being numerically interchangeable. This distinction also matters in composite disease scores: Roy Fleischmann and colleagues’ 2015 analysis of five rheumatoid arthritis trials found that applying DAS28-ESR thresholds to DAS28-CRP underestimated disease activity, with disagreement in remission classification ranging from 4% to 26%. The laboratory marker and the score formulation must therefore be specified when reporting disease activity. (medlineplus.gov)

High-Sensitivity CRP and Cardiovascular Risk

High-sensitivity CRP (hs-CRP) assays measure the same circulating protein as conventional CRP tests, but with greater precision at low concentrations. Their cardiovascular application concerns relatively small, persistent elevations that reflect low-level systemic inflammation, rather than the pronounced acute-phase response accompanying infection or tissue injury. Because atherosclerosis involves inflammatory processes, baseline hs-CRP provides a biomarker associated with the likelihood of future cardiovascular events. The measurement does not identify the anatomical source of inflammation or directly measure coronary plaque burden. Laboratory guidance therefore distinguishes hs-CRP testing for cardiovascular risk assessment from conventional CRP testing used to assess or monitor other inflammatory disorders. (mayocliniclabs.com)

The historical categories were formalized in a 2003 joint statement from the American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC), whose authors included Thomas A. Pearson and George A. Mensah. Concentrations below 1 mg/L, 1–3 mg/L, and above 3 mg/L represented low, average, and high relative cardiovascular risk, respectively. These cutpoints approximated thirds of the adult population distribution, using data from more than 40,000 people in over 15 populations; the highest category was associated with approximately twice the relative risk of the lowest. They were population-based risk strata, not diagnostic boundaries for coronary artery disease: a result above 3 mg/L did not establish coronary obstruction, and a result below 1 mg/L did not exclude it. (pubmed.ncbi.nlm.nih.gov)

Estimation of baseline inflammation also requires attention to temporary elevations. The 2003 statement described two measurements, preferably about two weeks apart, with their average providing a more stable estimate; fasting was not required. It treated a concentration above 10 mg/L differently from an ordinary cardiovascular risk result, specifying evaluation for infection or another inflammatory source and reassessment after the transient process had subsided. Thus, placing every acutely elevated value into the “above 3 mg/L” category would confuse an acute inflammatory response with the baseline signal used in cardiovascular prediction. Substantial within-person variability likewise means that one hs-CRP measurement may not represent an individual’s usual concentration. (ahajournals.org)

The explicitly dated 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease used a different, decision-oriented threshold: hs-CRP of at least 2.0 mg/L, if measured, was a risk-enhancing factor. In that framework, additional risk enhancers could inform preventive-treatment discussions for adults with borderline estimated 10-year atherosclerotic cardiovascular disease risk, 5% to below 7.5%, or intermediate risk, 7.5% to below 20%. The threshold supplemented broader assessment rather than defining disease or automatically determining treatment. For example, 2.5 mg/L falls within the historical 1–3 mg/L “average” category but meets the 2019 risk-enhancer threshold; the classifications differ because they serve different purposes. (pmc.ncbi.nlm.nih.gov)

Within the 2019 framework, absolute risk assessment remained grounded in established factors including age, smoking, blood pressure, diabetes, and blood cholesterol. Family history and other risk-enhancing conditions supplied further context. Consequently, a low hs-CRP value did not cancel risk attributable to these factors, while an elevated value was interpreted alongside them rather than replacing them. Cardiovascular interpretation asks whether a relatively stable inflammatory signal adds information about future event probability; inflammatory-disease interpretation instead examines the presence, magnitude, or course of an inflammatory response. These are distinct uses of the same blood protein, with different concentration thresholds and clinical questions. (pmc.ncbi.nlm.nih.gov)

Research Designs and the Distinction Between Association and Causation

Observational studies establish whether CRP concentration is associated with subsequent disease, not whether CRP itself produces that disease. Confounding can arise when factors influence both CRP and outcomes; reverse causation can arise when developing disease increases CRP before diagnosis. Consequently, a predictive biomarker need not be a causal mediator or an effective treatment target. These distinctions are central to interpreting CRP associations with coronary heart disease. (bmj.com)

Mendelian randomization uses inherited genetic variants associated with an exposure as instruments for causal inference. For CRP, the exposure is genetically influenced circulating concentration rather than a single blood-test result. Valid instruments must associate with CRP, be independent of exposure–outcome confounders, and affect the outcome only through CRP. Genetic inheritance reduces susceptibility to reverse causation, but does not automatically eliminate bias: population structure or effects of a variant through other biological pathways can violate these assumptions. Testing associations with measured confounders and comparing estimates from different instruments can assess plausibility, but cannot prove every assumption. (journals.plos.org)

The C Reactive Protein Coronary Heart Disease Genetics Collaboration’s 2011 individual-participant analysis included 194,418 people, including 46,557 with coronary heart disease, from 47 studies in 15 countries. Four CRP-associated variants—rs3093077, rs1205, rs1130864, and rs1800947—were associated with concentration differences of up to 30% per allele. The coronary risk ratio per one-standard-deviation increase in genetically predicted natural-log CRP was 1.00 (95% confidence interval 0.90–1.13), compared with 1.33 (1.23–1.43) for measured circulating CRP in prospective analyses. This discordance argued against circulating CRP concentration itself causing coronary disease; it did not negate CRP’s predictive association or test effects during acute ischemic injury. (bmj.com)

Structural and turnover experiments address different questions. In 1999, D. Thompson, Mark B. Pepys, and S. P. Wood used X-ray crystallography to examine calcium-bound CRP with and without phosphocholine, resolving molecular arrangements involved in ligand recognition. Such structures reveal binding geometry, not population-level disease effects. In 1993, D. M. Vigushin, Pepys, and P. N. Hawkins administered radioiodinated human CRP to eight healthy controls and 35 hospitalized patients. Similar clearance across the groups and an approximately 19-hour plasma half-life supported increased synthesis, rather than reduced clearance, as the determinant of elevated concentrations in those participants. This tracer experiment measured turnover; it did not establish whether elevated CRP caused their illnesses. (pubmed.ncbi.nlm.nih.gov)

Tissue localization identifies where a detectable CRP conformation occurs, whereas cell-based experiments test responses under controlled conditions. Steffen U. Eisenhardt and colleagues’ 2009 study detected monomeric CRP in human aortic and carotid atherosclerotic plaques and demonstrated pentamer dissociation on activated platelets and apoptotic cell surfaces. Experimental endpoints included monocyte migration, activation, reactive oxygen species generation, and adhesion. These observations supported a possible local mechanism, but neither tissue staining nor an experimentally induced cellular response, by itself, establishes that the mechanism causes clinical cardiovascular events. (pubmed.ncbi.nlm.nih.gov)

Validated clinical blood measurements and research measurements of tissue-associated conformations therefore require separate interpretation. Mayo Clinic Laboratories’ high-sensitivity serum assay, for example, quantifies CRP through antibody-coated latex-particle aggregation and turbidimetric detection, with performance verified under clinical laboratory requirements. It reports circulating concentration, not the location or abundance of monomeric CRP within plaques. Conformation-specific tissue detection and cellular functional assays measure different endpoints and are not interchangeable with that clinical blood result. (mayocliniclabs.com)

References

1. Serological Reactions in Pneumonia with a Non-Protein Somatic Fraction of Pneumococcuspmc.ncbi.nlm.nih.gov
2. The Rockefeller University: Hospital Centennialcentennial.rucares.org
3. Genomic DNA sequence for human C-reactive proteinpubmed.ncbi.nlm.nih.gov
4. Three dimensional structure of human C-reactive proteinpubmed.ncbi.nlm.nih.gov
5. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P componentpubmed.ncbi.nlm.nih.gov
6. The Phosphocholine-binding Pocket on C-reactive Protein Is Necessary for Initial Protection of Mice against Pneumococcal Infectionpmc.ncbi.nlm.nih.gov
7. PTX3 structure determination using a hybrid cryoelectron microscopy and AlphaFold approach offers insights into ligand binding and complement activationpmc.ncbi.nlm.nih.gov
8. The physiological structure of human C-reactive protein and its complex with phosphocholinepubmed.ncbi.nlm.nih.gov
9. C-reactive protein: structural biology and host defense function.pubmed.ncbi.nlm.nih.gov
10. CRP C-reactive protein [Homo sapiens (human)] - Gene - NCBIncbi.nlm.nih.gov
11. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes - PubMedpubmed.ncbi.nlm.nih.gov
12. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes - PubMedpubmed.ncbi.nlm.nih.gov
13. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6.pubmed.ncbi.nlm.nih.gov
14. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms - PMCpmc.ncbi.nlm.nih.gov
15. C-reactive protein: MedlinePlus Medical Encyclopediamedlineplus.gov
16. CRP - Overview: C-Reactive Protein (CRP), Serummayocliniclabs.com
17. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.jci.org
18. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complementpubmed.ncbi.nlm.nih.gov
19. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipidspubmed.ncbi.nlm.nih.gov
20. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosispubmed.ncbi.nlm.nih.gov
21. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptorspubmed.ncbi.nlm.nih.gov
22. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptorspubmed.ncbi.nlm.nih.gov
23. C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunitypmc.ncbi.nlm.nih.gov
24. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaquespubmed.ncbi.nlm.nih.gov
25. Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Proteinpmc.ncbi.nlm.nih.gov
26. In vitro generation and bioactivity evaluation of C-reactive protein intermediatepmc.ncbi.nlm.nih.gov
27. Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sitespmc.ncbi.nlm.nih.gov
28. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flowpubmed.ncbi.nlm.nih.gov
29. A redox sensitivity-based method to quantify both pentameric and monomeric C-reactive protein in a single assay.pubmed.ncbi.nlm.nih.gov
30. C-Reactive Protein (CRP) Test: MedlinePlus Medical Testmedlineplus.gov
31. Test Definition: HSCRP — C-Reactive Protein, High Sensitivity, Serummayocliniclabs.com
32. HSCRP — Overview: C-Reactive Protein, High Sensitivity, Serummayocliniclabs.com
33. CRP — Overview: C-Reactive Protein (CRP), Serummayocliniclabs.com
34. CRPHS, Cardiac C-Reactive Protein (Latex) High Sensitivediagnostics.roche.com
35. CRPHS: Cardiac C-Reactive Protein (Latex) High Sensitive — Method Sheet, May 2024, Version 11.0elabdoc-prod.roche.com
36. C-Reactive Protein (CRP), Serum — Mayo Clinic Laboratoriesmayocliniclabs.com
37. How to Understand Your Lab Results: MedlinePlus Medical Testmedlineplus.gov
38. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal womenpubmed.ncbi.nlm.nih.gov
39. Usefulness of C-reactive protein for evaluating clinical outcomes in cirrhotic patients with bacteremiapubmed.ncbi.nlm.nih.gov
40. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infectionspubmed.ncbi.nlm.nih.gov
41. Recommendations | Pneumonia: diagnosis and management | Guidance | NICEnice.org.uk
42. Managing suspected sepsis | Suspected sepsis in people aged 16 or over: recognition, assessment and early management | Guidance | NICEnice.org.uk
43. Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritispmc.ncbi.nlm.nih.gov
44. The role of biomarkers for the management of Crohn's disease - American Gastroenterological Associationgastro.org
45. Clinical utility of peri-operative C-reactive protein testing in general surgerypubmed.ncbi.nlm.nih.gov
46. Fever, leucocytosis and C-reactive protein after open-heart surgery and their value in the diagnosis of postoperative infectionspubmed.ncbi.nlm.nih.gov
47. Erythrocyte Sedimentation Rate (ESR): MedlinePlus Medical Testmedlineplus.gov
48. Markers of inflammation and cardiovascular disease: application to clinical and public health practicepubmed.ncbi.nlm.nih.gov
49. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Diseasepmc.ncbi.nlm.nih.gov
50. Ten simple rules for conducting a mendelian randomization studyjournals.plos.org
51. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.jci.org